On this special episode of the podcast, Emilia Javorsky interviews Sean Ekins about regulating AI drug discovery.
Timestramps:
00:00 Introduction
00:31 Ethical guidelines and regulation of AI drug discovery
06:11 How do we balance innovation and safety in AI drug discovery?
13:12 Keeping dangerous chemical data safe
21:16 Sean’s personal story of voicing concerns about AI drug discovery
32:06 How Sean will continue working on AI drug discovery
Peter Wildeford discusses methods for forecasting AI progress and why he sees AI as neither a bubble nor a normal technology, covering economic effects, national security, cyber capabilities, robotics, export controls, and prediction markets.
View episode
Inria researcher Carina Prunkl discusses why AI evaluation struggles to keep pace with general-purpose systems, including jagged capabilities, missed real-world behavior, misuse risks, de-skilling, red teaming, and layered safeguards.
View episode
Li-Lian Ang from Blue Dot Impact discusses how to build a workforce to defend against AI-driven risks, including engineered pandemics, cyber attacks, job disempowerment, and concentrated power, using a defense-in-depth framework for uncertain AI progress.
View episodeNo matter your level of experience or seniority, there is something you can do to help us ensure the future of life is positive.
